Every Form 4 that Brainstorm Cell Therapeutics I (BCLI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BCLI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCLI filings page.
FRENKEL JACOB A reported acquisition or exercise transactions in this Form 4 filing.
BrainStorm Cell Therapeutics Inc. reported that director Jacob A. Frenkel received a grant of 100,000 restricted stock units (RSUs) representing common stock under a Consulting Agreement dated July 24, 2026 and the 2014 Global Share Option Plan. The RSUs vest 50% on October 24, 2026 and 50% on April 24, 2027, contingent on continued service. Following this equity award, his direct holdings are reported at 343,777 shares of common stock.
Brainstorm Cell Therapeutics Inc. reported that Executive Chairman Peter Joe Pitts received a grant of 900,000 stock options on July 24, 2026. The options have a $1.00 exercise price, are exercisable for 900,000 common shares, expire on July 24, 2036, and vest over 48 months subject to continued employment.
Lebovits Chaim reported acquisition or exercise transactions in this Form 4 filing.
BrainStorm Cell Therapeutics President & CEO Chaim Lebovits reported an award of 1,800,000 shares of common stock in the form of restricted stock units under the company’s equity plan. The RSUs vest 50% on the February 26, 2026 grant date and 50% on the six‑month anniversary, contingent on his continued employment. Following this compensation grant, he holds 2,000,960 shares of common stock directly.
Yablonka Uri reported acquisition or exercise transactions in this Form 4 filing.
BrainStorm Cell Therapeutics executive Uri Yablonka received a grant of 150,000 shares of common stock in the form of restricted stock units. According to the award terms, 50% of the RSUs vest on the grant date and the remaining 50% vest six months later, contingent on continued employment. Following this compensation grant, Yablonka holds 218,464 shares directly.
Patlis Alla reported acquisition or exercise transactions in this Form 4 filing.
Brainstorm Cell Therapeutics Inc. reported that officer Alla Patlis received a grant of 100,000 shares of Common Stock in the form of restricted stock units (RSUs) at no cash cost per share. Following this award, Patlis directly holds 144,349 shares.
According to the terms, 50% of the RSU award vests on the grant date and the remaining 50% vests on the six‑month anniversary of the grant, as long as Patlis remains employed by the company through each vesting date. This filing reflects a compensation-related equity grant rather than an open‑market share purchase or sale.
FRENKEL JACOB A reported acquisition or exercise transactions in this Form 4 filing.
BrainStorm Cell Therapeutics director Jacob A. Frenkel received a grant of 200,000 shares of Common Stock in the form of restricted stock units. The award was made at a stated price of $0.00 per share as stock-based compensation, rather than an open-market purchase.
According to the grant terms, 50% of the RSUs vest on the grant date and the remaining 50% vest on the six-month anniversary of that date, if he remains employed by the company. After this award, Frenkel directly holds 243,777 shares of the company’s stock.
ARBEL IRIT reported acquisition or exercise transactions in this Form 4 filing.
Brainstorm Cell Therapeutics director Irit Arbel received an equity award of 120,000 shares of Common Stock in the form of restricted stock units. The grant was made on February 26, 2026 at a stated price of $0.00 per share, indicating it is compensation rather than an open-market purchase.
The RSUs were awarded under the company’s 2014 Global Share Option Plan. According to the terms, 50% of the RSUs vest on the grant date and the remaining 50% vest on the six‑month anniversary of the grant date, as long as Arbel remains employed by the company through each vesting date. After this award, Arbel’s reported direct holdings total 161,054 shares of Common Stock.
Bairu Menghisteab reported acquisition or exercise transactions in this Form 4 filing.
BRAINSTORM CELL THERAPEUTICS INC. director Menghisteab Bairu received a grant of stock options to buy 150,000 shares of common stock at $0.70 per share. These options, granted under the company’s 2014 Stock Incentive Plan, expire on February 26, 2036.
The award vests over a short schedule: 50% of the options vest on the grant date and the remaining 50% vest on the six-month anniversary, as long as Bairu remains employed by the company through each vesting date. Following this grant, Bairu holds 150,000 stock options directly.
BrainStorm Cell Therapeutics director Anthony J. Polverino received a grant of stock options to acquire 150,000 shares of common stock at an exercise price of $0.70 per share. These options were granted under the company’s 2014 Stock Incentive Plan and are a form of equity compensation.
The options vest in two equal parts: 50% vests on the grant date and the remaining 50% vests on the six-month anniversary of the grant, provided he remains employed through each vesting date. All 150,000 options are scheduled to expire on February 26, 2036, giving a long-dated incentive tied to the company’s share performance.
HARTOUNIAN HARTOUN reported acquisition or exercise transactions in this Form 4 filing.
BRAINSTORM CELL THERAPEUTICS INC. director Hartoun Hartoun received a grant of stock options to buy 225,000 shares of common stock at $0.70 per share. These options were granted under the company’s 2014 Stock Incentive Plan and expire on February 26, 2036.
The award vests over a short period: 50% of the options vest on the grant date and the remaining 50% vest on the six‑month anniversary, as long as Hartoun remains employed through each vesting date. After this grant, he holds 225,000 stock options directly.
Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.
BRAINSTORM CELL THERAPEUTICS INC. director Stacy Lindborg received a grant of stock options to buy 150,000 shares of common stock at $0.70 per share. All 150,000 options were outstanding after the grant.
The options were granted under the company’s 2014 Stock Incentive Plan. According to the terms, 50% of the award vests on the grant date and the remaining 50% vests on the six-month anniversary of the grant date, provided she remains employed through each vesting date. The options expire on February 26, 2036, giving a long-dated incentive tied to the company’s future share performance.
BrainStorm Cell Therapeutics director Naor Nir received a new stock option grant. He was awarded options to buy 180,000 shares of common stock at an exercise price of $0.70 per share under the company’s 2014 Stock Incentive Plan.
According to the vesting terms, 50% of the options vest on the grant date, and the remaining 50% vest on the six‑month anniversary of the grant date, provided he remains employed by the company through each vesting date. Following this award, he holds options covering 180,000 shares from this grant, which expire on February 26, 2036.
BRAINSTORM CELL THERAPEUTICS INC. director Ibrahim B. Dagher received a grant of stock options to acquire 225,000 shares of common stock at an exercise price of $0.70 per share. These options were granted under the company’s 2014 Stock Incentive Plan as equity-based compensation.
According to the vesting terms, 50% of the award vests on the grant date and the remaining 50% vests on the six-month anniversary of the grant date, as long as Dagher remains employed by the company through each vesting date. Following this grant, his reported holdings in this option series total 225,000 options, which are scheduled to expire on February 26, 2036.